{"filings":[{"id":1567996,"accession_number":"0001477932-26-004240","cik":1477960,"company_name":"LataMed AI Corp.","ticker":"CCTC","form_type":"8-K","filed_at":"2026-07-10T14:51:27+00:00","items":["5.03","9.01"],"status":"ready","headline":"LataMed AI Corp. increases authorized shares 5x and effects 5:1 forward stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 700M to 3.5B shares; preferred from 300M to 1.5B shares.","5:1 forward split of issued and outstanding common shares effective July 2, 2026.","Certificate of Change filed with Nevada Secretary of State on July 2, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":151100000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93085,"accession_number":"0001477932-26-002848","cik":1477960,"company_name":"LataMed AI Corp.","ticker":"CCTC","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Latamed AI Corp. authorizes 5M shares of Series C Voting Preferred Stock (20 votes/share)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board designated Series C Voting Preferred Stock: 5,000,000 shares authorized, non-convertible, non-redeemable.","Each Series C share carries 20 votes, voting with common stock as a single class on all matters.","Liquidation preference senior to common stock; dividends at board's discretion, subject to senior securities.","Protective provisions require majority vote of Series C holders for actions that create senior stock, amend terms, or dissolve company.","Certificate of Designation filed with Nevada Secretary of State on May 6, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":151100000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93084,"accession_number":"0001477932-26-002735","cik":1477960,"company_name":"LataMed AI Corp.","ticker":"CCTC","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Catalyst Crew Technologies Corp. changes name to LataMed AI Corp.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change effective April 28, 2026 upon filing Certificate of Amendment with Nevada Secretary of State.","The sole change is the corporate name; all other Articles of Incorporation provisions remain unchanged.","Company is a Nevada corporation; address in Caracas, Venezuela."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":151100000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93083,"accession_number":"0001477932-26-002171","cik":1477960,"company_name":"LataMed AI Corp.","ticker":"CCTC","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Catalyst Crew acquires AI healthcare IP and Venezuelan subsidiary from CEO in related-party transactions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acquired AI healthcare analytics IP (CardioAI, PulmoAI, NeuroAI) from CEO via APA dated Feb 17, 2026.","Acquired 100% of Inversiones Long 33, C.A. from CEO on March 23, 2026; now wholly-owned subsidiary.","IP formally assigned to subsidiary on April 7, 2026 as internal reorganization; no additional consideration.","Press releases issued March-April 2026 announcing CardioAI, PulmoAI, NeuroAI platforms and operating structure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151100000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93082,"accession_number":"0001477932-26-002061","cik":1477960,"company_name":"LataMed AI Corp.","ticker":"CCTC","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Catalyst Crew Technologies appoints Carlos Peña as CFO effective March 31, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carlos Peña, 38, appointed CFO; over 10 years experience in accounting, financial management, and audit.","Since March 2024, Peña served as Supervisor of Administration and Finance for Aerovip, an aviation firm.","No formal employment agreement or finalized compensation with Peña as of report date.","No family relationships or arrangements with any director/officer; no related transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":151100000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104416,"accession_number":"0001477932-26-001029","cik":1477960,"company_name":"LataMed AI Corp.","ticker":"CCTC","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["5.06","1.01","2.01","3.02","5.01","5.02","9.01"],"status":"ready","headline":"Catalyst Crew Technologies completes asset acquisition and change of control, exits shell company status","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired AI healthcare analytics platform and medical services assets from Kevin Rodan Levy for 12,000,000 restricted shares.","Kevin Rodan Levy purchased 28,000,000 shares from Andrew Gaudet for $10,000, becoming majority owner with 71.1% ownership.","Former directors Andrew Gaudet, Waqas Nakhwa, Navneet B. Tayal, and Vineet Jawa resigned; Levy appointed sole director and CEO, CFO, Secretary, and Treasurer.","Company ceased to be a shell company following the asset acquisition and intends to operate as a digital health technology firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":151100000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190166,"accession_number":"0001477932-24-007001","cik":1477960,"company_name":"LataMed AI Corp.","ticker":"CCTC","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Catalyst Crew appoints Waqas Nakhwa as CEO/CFO/Chairman; grants 25M restricted shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Waqas Nakhwa named CEO, President, CFO, Treasurer, Secretary, and Chairman effective Nov 6, 2024.","Base salary set at $5,000 per month, first payment due in January 2025; 12-month term.","One-time equity award of 25,000,000 restricted shares at $0.0001 cost basis issued upon Effective Date.","Employment is at-will; may be terminated by either party without cause.","No information provided on prior CEO departure or transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":151100000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190165,"accession_number":"0001477932-24-006784","cik":1477960,"company_name":"LataMed AI Corp.","ticker":"CCTC","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catalyst Crew Tech completes 450-for-1 reverse split, ticker change to CCTC effective Oct 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change to Catalyst Crew Technologies Corp and ticker change to CCTC effective Oct 14, 2024, after 20-day 'D' suffix period.","450-for-1 reverse split reduced outstanding shares from ~109.6M to ~243,632; fractional shares rounded up.","New CUSIP 21116R305; no action required from current shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":151100000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206675,"accession_number":"0001477932-24-004973","cik":1477960,"company_name":"LataMed AI Corp.","ticker":"CCTC","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Catalyst Crew Technologies (fka Blue Chip) approves 450:1 reverse split and name change","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change from Blue Chip Technologies Corp. to Catalyst Crew Technologies Corp. effective August 12, 2024.","Authorized 450-for-1 reverse stock split; outstanding shares to reduce from ~109.6M to ~243,632.","Fractional shares resulting from reverse split will be rounded up to next whole share.","FINRA filing submitted July 17, 2024 for new stock symbol and to effect reverse split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151100000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223865,"accession_number":"0001477932-24-003696","cik":1477960,"company_name":"LataMed AI Corp.","ticker":"CCTC","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CEO Gurneet Kaur resigns; Waqas Nakhwa appointed CEO and Chairman with 66.5% stake","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gurneet Kaur resigned as President, CEO, CFO, Secretary, and Director effective June 7, 2024; no disagreement.","Waqas Nakhwa appointed President, CEO, CFO, Treasurer, Secretary, and Chairman effective June 7, 2024.","Sameer Kudsia resigned as independent director; Vineet Jawa appointed independent director effective June 7, 2024.","Nakhwa beneficially owns 72,944,965 shares (66.53% of 109,634,536 outstanding), gaining controlling interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":151100000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243255,"accession_number":"0001477932-24-001193","cik":1477960,"company_name":"LataMed AI Corp.","ticker":"CCTC","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Blue Chip Technologies dismisses Gries & Associates, appoints Beckles & Co as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Gries & Associates, LLC as independent auditor on March 12, 2024; board approved.","Gries' 2022 audit report contained a going concern uncertainty paragraph; no disagreements reported for 2021-2022.","Appointed Beckles & Co, Inc. CPA as new independent auditor effective March 12, 2024.","Company provided Gries with a copy of the report; Gries' letter filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151100000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}